for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Halozyme Says FDA Accepted BLA For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology

Feb 25 (Reuters) - Halozyme Therapeutics Inc:

* HALOZYME ANNOUNCES FDA HAS ACCEPTED BIOLOGICS LICENSE APPLICATION FOR FIXED-DOSE SUBCUTANEOUS COMBINATION OF PERJETA® AND HERCEPTIN® USING ENHANZE® TECHNOLOGY

* U.S. FOOD DRUG AND ADMINISTRATION EXPECTED TO DECIDE ON APPROVAL BY OCTOBER 18, 2020 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up